Work

Patient characteristics and overall survival with lutetium (Lu 177 ) vipivotide tetraxetan ( 177 Lu-PSMA-617): A real-world analysis of early adopters.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.63

Authors: Daniel J. George, Neal D. Shore, Jennifer Nguyen, Jeetvan Patel, Amrita Sawhney, Barinder Kang, Chi-Chang Chen, Magdaliz Gorritz, Xiao X. Wei

Institutions: Duke University, Duke Medical Center, Duke Cancer Institute, Carolina Urologic Research Center, IQVIA (United States), Dana-Farber Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W4407700866

Cites:

Cited by:

Related to: 10